Rivaroxaban Tablets (Xarelto)

Elliott, William T.; Chan, James
August 2011
Internal Medicine Alert;8/15/2011, Vol. 33 Issue 15, p117
The article offers information on the drug for the treatment of deep vein thrombosis (DVT), Rivaroxaban, which was developed by Bayer in the U.S.


Related Articles

  • Home treatment for deep-vein thrombosis is safe and effective.  // Modern Medicine;Jul96, Vol. 64 Issue 7, p60 

    Presents an abstract on articles about the safety of deep-vein thrombosis home treatments by M. Levine, M.M.W. Koopman et al published in the March 14, 1996 issue of the `New England Journal of Medicine'.

  • Antithrombotic agent.  // Geriatrics;June97, Vol. 52 Issue 6, p21 

    Focuses on danaparoid sodium (Orgaran) injection for prevention of postoperative deep vein thrombosis (DVT) in patients undergoing elective hip replacement surgery. Recommended dosage of the agent; Most common adverse reactions of the agent.

  • Using published, institutional data to evaluate the cost effectiveness of DVT prophylaxis. Wade, William E.; Taylor, A. Thomas // Formulary;Dec96, Vol. 31 Issue 12, p1203 

    Reviews the pharmacologic therapies for deep vein thrombosis (DVT) prophylaxis in patients undergoing major orthopedic surgery. Prevention of DVT; Use of low molecular weight herpins; Administering the drug to total hip replacement and knee replacement surgery patients. INSET: Treatment of DVT..

  • Bilateral ultrasonography for evaluation of suspected DVT. Apgar, Barbara // American Family Physician;12/1/1996, Vol. 54 Issue 8, p2552 

    Presents a summary of the article `Suspected Deep Venous Thrombosis: Is US of Both Legs Necessary?,' by J.B. Naidich, et al from the journal `Radiology' dated 1996. Methodology of the study; Signs and symptoms of deep venous thrombosis; Outcome of the study; Conclusion.

  • Thinner is better? Schwade, Steve // Prevention;Sep96, Vol. 48 Issue 9, p51 

    Examines deepvein thrombosis (DVT). Disorder that forms blood clots in the legs of people with DVT; Suggestion that a drug called low-molecular-weight heparin (LMWH) can help people with DVT treat themselves; Results of a study of people who used LMWH.

  • Outpatient low-molecular-weight heparin vs. in-hospital heparin for proximal DVT. Simonelli, Paul F. // Cortlandt Forum;11/25/97, Vol. 10 Issue 11, p38 

    Examines the results of a study supporting the evolving practice of limited in-hospital treatment of proximal lower-extremity deep vein thrombosis. Comparison of the treatment mode with standard continuous intravenous heparin; Impact of hospital stay; Rate of symptomatic recurrence.

  • Management of deep-vein thrombosis. Francis, Charles W.; Kerr, Colin P. // JAMA: Journal of the American Medical Association;2/16/94, Vol. 271 Issue 7, p556 

    Answers questions on the management of deep-vein thrombosis. Lack of clinical studies on return to ambulation and normal activity after treatment; Response to bed rest and anticoagulant therapy; Years to develop chronic venous insufficiency.

  • Patient preference & treatment decisions. Levin, Arthur Aaron // HealthFacts;Aug94, Vol. 19 Issue 183, p2 

    Discusses patient preference in an effort to resolve uncertainty about the best drug treatment for deep-vein thrombosis (DVT). Description of DVT; Uncertainty on using heparin alone in treating DVT or adding thrombolytic to the medication; Review of studies of DVT drug treatment by Doctor James...

  • Breaking out of the silo:One health system's experience. Vichiendilokkul, Anna // American Journal of Health-System Pharmacy;10/15/2002, Vol. 59 Issue 20, pS15 

    Pharmacoeconomic evidence for inpatient deep vein thrombosis (DVT) treatment with low-molecular-weight heparins (LMWHs) and one health system's experience with this treatment compared with unfractionated heparins (UFHs) are examined, Applying clinical and pharmacoeconomic evidence to clinical...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics